L.J.C. van Warmerdam

1.1k citations

33 papers · 830 indexed · h-index 16

Co-authors: Jos H. Beijnen R. A. A. Maes W.W. ten Bokkel Huinink Sjoerd Rodenhuis Hilde Rosing Jan H.M. Schellens Olaf van Tellingen M de Boer-Dennert
Topics: Cancer Treatment and Pharmacology (13 papers)Breast Cancer Treatment Studies (9 papers)Chemotherapy-induced organ toxicity mitigation (8 papers)
Cited by: Oncology Pathology and Forensic Medicine Cancer Research
Journals: Journal of Clinical Oncology Annals of Oncology European Journal of Cancer
Partner nations: Netherlands United States Germany

In The Last Decade

L.J.C. van Warmerdam

33 papers receiving 803 citations

Peers

Countries citing papers authored by L.J.C. van Warmerdam

Since Specialization

Citations

This map shows the geographic impact of L.J.C. van Warmerdam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L.J.C. van Warmerdam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L.J.C. van Warmerdam more than expected).

Fields of papers citing papers by L.J.C. van Warmerdam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L.J.C. van Warmerdam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L.J.C. van Warmerdam. The network helps show where L.J.C. van Warmerdam may publish in the future.

Co-authorship network of co-authors of L.J.C. van Warmerdam

This figure shows the co-authorship network connecting the top 25 collaborators of L.J.C. van Warmerdam. A scholar is included among the top collaborators of L.J.C. van Warmerdam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L.J.C. van Warmerdam. L.J.C. van Warmerdam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy – A two center cohort study 2024 ·European Journal of Surgical Oncology ·Robert‐Jan Schipper,(unknown),Maurice J.C. van der Sangen,(unknown),(unknown),(unknown),(unknown),(unknown),Dorien Rijkaart,(unknown),(unknown),L.J.C. van Warmerdam,(unknown),(unknown),(unknown),(unknown),Grard A. P. Nieuwenhuijzen	4
2	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01) 2019 ·Breast Cancer Research ·Stefanie de Groot,Hanno Pijl,Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Hein Putter,Marta Fiocco,Gerrit‐Jan Liefers,Jacobus J. M. van der Hoeven,J.W.R. Nortier,Judith R. Kroep	7
3	Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status 2018 ·The Breast Journal ·Guusje Vugts,(unknown),Adriana J. G. Maaskant-Braat,Adri C. Voogd,L.J.C. van Warmerdam,Grard A. P. Nieuwenhuijzen,Maurice J.C. van der Sangen	5
4	Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG) 2018 ·Breast Cancer Research and Treatment ·(unknown),Monique E.M.M. Bos,Marta López‐Yurda,(unknown),Jeany M. Rademaker-Lakhai,Aafke H. Honkoop,Hiltje de Graaf,(unknown),L.J.C. van Warmerdam,Maurice J.C. van der Sangen,Vivianne C. G. Tjan‐Heijnen,Frans Erdkamp	12
5	Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer 2017 ·Breast Cancer Research and Treatment ·Birgit E. P. J. Vriens,Ingeborg J. H. Vriens,Maureen J.B. Aarts,(unknown),Franchette W.P.J. van den Berkmortel,Tineke J. Smilde,L.J.C. van Warmerdam,D.J. van Spronsen,P.G.M. Peer,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen,(unknown)	10
6	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) 2014 ·Annals of Oncology ·Ayoub Charehbili,Saskia van de Ven,Vincent T.H.B.M. Smit,Elma Meershoek‐Klein Kranenbarg,N.A.T. Hamdy,Hein Putter,Joan B. Heijns,L.J.C. van Warmerdam,Lonneke W. Kessels,M. Wouter Dercksen,Manon J. Pepels,E. Maartense,Hanneke W.M. van Laarhoven,Birgit E. P. J. Vriens,Martin N.J.M. Wasser,A. Elise van Leeuwen‐Stok,Gerrit‐Jan Liefers,C.J.H. van de Velde,J. W. R. Nortier,Judith R. Kroep	31
7	Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 2013 ·European Journal of Cancer ·Birgit E. P. J. Vriens,Maureen J.B. Aarts,Bart de Vries,(unknown),J. Wals,Tineke J. Smilde,L.J.C. van Warmerdam,Maaike de Boer,D.J. van Spronsen,George F. Borm,Vivianne C. G. Tjan‐Heijnen	31
8	Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer 2013 ·Clinical Therapeutics ·Marije Slingerland,Henk‐Jan Guchelaar,Hilde Rosing,M. E. Scheulen,L.J.C. van Warmerdam,Jos H. Beijnen,Hans Gelderblom	69
9	Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience 2013 ·Clinical Oncology ·Irene E.G. van Hellemond,G.J. Creemers,L.J.C. van Warmerdam,Floris A. de Jong,Rutger H.T. Koornstra	2
10	A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen 1999 ·Cancer Chemotherapy and Pharmacology ·Vinodh R. Nannan Panday,L.J.C. van Warmerdam,Manon Huizing,Sjoerd Rodenhuis,Jan H.M. Schellens,Jos H. Beijnen	11
11	A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel 1999 ·Journal of Cancer Research and Clinical Oncology ·Vinodh R. Nannan Panday,L.J.C. van Warmerdam,Manon Huizing,W.W. ten Bokkel Huinink,Jan H.M. Schellens,Jos H. Beijnen	11
12	PHARMACOLOGIC STUDY OF 3-HOUR 135 mg m−2PACLITAXEL IN PLATINUM PRETREATED PATIENTS WITH ADVANCED OVARIAN CANCER 1998 ·Pharmacological Research ·Vinodh R. Nannan Panday,Manon Huizing,L.J.C. van Warmerdam,R. Dubbelman,Ingrid A.M. Mandjes,Jan H.M. Schellens,W.W. ten Bokkel Huinink,Jos H. Beijnen	9
13	Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens 1998 ·Clinical Drug Investigation ·Vinodh R. Nannan Panday,L.J.C. van Warmerdam,Manon Huizing,W.W. ten Bokkel Huinink,Jan B. Vermorken,Giuseppe Giaccone,C.H.N. Veenhof,Jan H.M. Schellens,Jos H. Beijnen	8
14	Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure 1996 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Geert‐Jan Creemers,Sjoerd Rodenhuis,Hilde Rosing,M de Boer-Dennert,Jan H.M. Schellens,W.W. ten Bokkel Huinink,Brian E. Davies,R. A. A. Maes,Jaap Verweij,Jos H. Beijnen	32
15	Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks 1995 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Jaap Verweij,Jan H.M. Schellens,Hilde Rosing,Brian E. Davies,M de Boer-Dennert,R. A. A. Maes,J. H. Beijnen	84
16	Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin 1995 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Sjoerd Rodenhuis,W.W. ten Bokkel Huinink,R. A. A. Maes,Jos H. Beijnen	38
17	Monitoring Carboplatin Concentrations in Saliva 1995 ·Therapeutic Drug Monitoring ·L.J.C. van Warmerdam,Olaf van Tellingen,W.W. ten Bokkel Huinink,Sjoerd Rodenhuis,R. A. A. Maes,Jos H. Beijnen	15
18	Limited-sampling models for anticancer agents 1994 ·Journal of Cancer Research and Clinical Oncology ·L.J.C. van Warmerdam,W.W. ten Bokkel Huinink,R. A. A. Maes,Jos H. Beijnen	61
19	Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination 1994 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Sjoerd Rodenhuis,(unknown),R. A. A. Maes,Jos H. Beijnen	20
20	Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks 1994 ·Cancer Chemotherapy and Pharmacology ·L.J.C. van Warmerdam,Jaap Verweij,Jan H.M. Schellens,Hilde Rosing,Brian E. Davies,M de Boer-Dennert,Jos H. Beijnen,(unknown)	4

About L.J.C. van Warmerdam

L.J.C. van Warmerdam is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 33 papers that have together received 830 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (9 papers) and Chemotherapy-induced organ toxicity mitigation (8 papers). The work is most often cited by research in Oncology (486 citations), Pathology and Forensic Medicine (216 citations) and Cancer Research (156 citations). L.J.C. van Warmerdam has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Jos H. Beijnen, R. A. A. Maes, W.W. ten Bokkel Huinink, Sjoerd Rodenhuis, Hilde Rosing, Jan H.M. Schellens, Olaf van Tellingen, R. A. A. Maes, M de Boer-Dennert and Manon Huizing. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact